Literature DB >> 19145388

[The IASLC lung cancer staging project. Comparing the current 6(th) TNM edition with the proposed 7(th) edition].

Lina Carvalho, Edgar Cardoso, Henrique Nunes, Victor Baptista, Ana Gomes, Patrícia Couceiro.   

Abstract

The future 7th edition of TNM classification for lung cancer will be published in 2009 and comprises the IASLC recommendations for TNM parameters. The general staging of lung cancer includes the new parameters: reclassification of tumours larger than 7 cm from T2 to T3; extra tumoral nodules will change their category to T3, T4 and M1 when in the same, ipsilateral or contralateral lobe, respectively; pleural effusion will be M1a. With these alterations, cases staged as IB - T2b N0 M0 will be IIA, cases staged IIB - T2a N1 M0 will be IIA and cases IIIB- T4 N0- -1 M0 will be IIIA. The 7(th) TNM edition recommendations were applied to 203 broncho -pulmonary carcinomas, concerning epidermoid carcinomas (83) and adenocarcinomas (120) registered in the archive of the Serviço de Anatomia Patológica of the Hospitais da Universidade de Coimbra - Portugal, previously submitted to surgical resection and lymph node excision. The following alterations will be kept as the application of the future 7(th) TNM edition: 20 cases in stage IB will move to stage IIA (17) and stage IIB (3); 18 cases will change from stage IIB to stage IIA (17) and 1 case to stage IIIA; 2 cases from stage IIIB will move to stage IV; 6 cases in stage IV will move to stage IIIA (5) and 1 case to stage IIIB. In this translational adaptation from 6th to 7th TNM staging, 51 out of the 203 analysed cases change their staging, corresponding to 25.1%.

Entities:  

Mesh:

Year:  2009        PMID: 19145388     DOI: 10.1016/s0873-2159(15)30110-0

Source DB:  PubMed          Journal:  Rev Port Pneumol        ISSN: 0873-2159


  7 in total

Review 1.  Lung cancer: Biology and treatment options.

Authors:  Hassan Lemjabbar-Alaoui; Omer Ui Hassan; Yi-Wei Yang; Petra Buchanan
Journal:  Biochim Biophys Acta       Date:  2015-08-19

2.  Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies.

Authors:  Ramon Andrade de Mello; Dânia Sofia Marques; Rui Medeiros; António Mf Araújo
Journal:  World J Clin Oncol       Date:  2011-11-10

3.  Association between EGF +61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a case-control study.

Authors:  Ramon Andrade de Mello; Mónica Ferreira; Sandra Costa; Bruno Marques Costa; Filipa Soares Pires; Inês Neves; Maria Inês Almeida; João Cunha; Pedro Oliveira; Venceslau Hespanhol; Rui Manuel Reis
Journal:  Tumour Biol       Date:  2012-03-29

4.  Staging of lung cancer in a tertiary care setting in Sri Lanka, using TNM 7th edition. A comparison against TNM6.

Authors:  Dinesh L B Dassanayake; Thushara M Muthunayake; Kapila H M P Senevirathna; Anoma Siribaddana
Journal:  BMC Res Notes       Date:  2012-03-14

5.  EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study.

Authors:  Ramon Andrade de Mello; Filipa Soares Pires; Dânia Sofia Marques; Júlio Oliveira; Ana Rodrigues; Marta Soares; Isabel Azevedo; Ana Peixoto; Catarina Santos; Carla Pinto; Venceslau Hespanhol; Manuel R Teixeira; Teresina Amaro; Henrique Queiroga; António Araújo
Journal:  Tumour Biol       Date:  2012-07-29

6.  Modification of Pathologic T Classification for Non-small Cell Lung Cancer With Visceral Pleural Invasion: Data From 1,055 Cases of Cancers ≤ 3 cm.

Authors:  Run-Bin Liang; Peng Li; Bob T Li; Jie-Tian Jin; Valerie W Rusch; David R Jones; Yi-Long Wu; Qing Liu; Jie Yang; Mu-Zi Yang; Shuo Li; Hao Long; Jian-Hua Fu; Lan-Jun Zhang; Peng Lin; Tie-Hua Rong; Xue Hou; Su-Xia Lin; Hao-Xian Yang
Journal:  Chest       Date:  2021-03-18       Impact factor: 9.410

7.  The impact of polymorphic variations in the 5p15, 6p12, 6p21 and 15q25 Loci on the risk and prognosis of portuguese patients with non-small cell lung cancer.

Authors:  Ramon Andrade de Mello; Mónica Ferreira; Filipa Soares-Pires; Sandra Costa; João Cunha; Pedro Oliveira; Venceslau Hespanhol; Rui Manuel Reis
Journal:  PLoS One       Date:  2013-09-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.